I-ACT: Phase I trial of Amnion Cell Therapy for Ischaemic Stroke to establish the maximum tolerable dose

I-ACT：羊膜细胞疗法治疗缺血性中风的 I 期试验，以确定最大耐受剂量

• 批准号: nhmrc : GNT1163282
• 金额: $ 71.1万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2019
• 资助国家: 澳大利亚
• 起止时间: 2019-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/i-act-phase-tolerable-dose/1379286
• 关键词: ACT; Phase; trial; Amnion; Cell

Ischaemic stroke, resulting from an obstructive clot, comprised approximately 85% of all strokes. There are several new therapies including the clot-busting drug, and clot retrieval (ECR) for large clots . However, only a small subset of patients are eligible for these therapies. We have demonstrated that human amnionic stem cell can reduce stroke size in animal experiments. We thus propose a Phase 1 dose escalation trial to assess the safety of allogeneic stem cell in stroke patients.

梗阻性血块引起的缺血性中风约占所有中风的85%。有几种新的治疗方法，包括抗凝血药物和用于大凝块的凝块恢复（ECR）。然而，只有一小部分患者有资格接受这些治疗。我们已经在动物实验中证明了人羊膜干细胞可以减小脑卒中的大小。因此，我们建议进行1期剂量递增试验，以评估同种异体干细胞在卒中患者中的安全性。